REMARKS

Claims 1-30 are active in the present application. Claims 7, 9, 10, 12 and 15 have been amended to remove multiple dependencies. The specification has been amended to correct a typographical error. No new matter is added. Action on the merits and allowance of the claims is solicited.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND, MAIER & NEUSTADT, P.C.

Norman F. Oblon Attorney of Record Registration No. 24,618

Daniel J. Pereira, Ph.D. Registration No. 45,518

22850

(703) 413-3000 NFO/DJP/smi

I:\atty\SUKOS\213966US-pr.wpd

213966US-0PCT

Marked-Up Copy

Serial No:

Amendment Filed on: 09-24-01

<u>IN THE</u> <u>SPECIFICATION</u>

Please replace the last paragraph on page 17, lines 23 and 24 through page 18, line 6, with the following paragraph:

--Specifically, 300 μl of a fist reagent, a 50 mM MES buffer (pH 6.5) containing 0.005% (40 [μm] μM) digitonin, was added to 3 μl of the samples. After 5 minutes, 100 μl of a cholesterol determination reagent (a second reagent), which is a 50 mM phosphate buffer (pH 6.5) containing 1% Emulgen B-66, 1 U/ml cholesterol esterase, 1 U/ml cholesterol oxidase, 5 U/ml peroxidase, 0.04% disulfobutyl-m-toluidine, and 0.004% 4-aminoantipyrine, was added.--

IN THE CLAIMS

Please amend the claims as follows.

- --7. (Amended) The method according to claim 1 [or claim 6], wherein the compound having a relatively strong affinity with the non-measuring lipoproteins in the sample is a saponin.
- 9. (Amended) The method according to claim 7 [or claim 8], wherein the saponin is digitonin or tomatine.
- 10. (Amended) The method according to claim 1 [or claim 6], wherein the compound having a relatively strong affinity with the non-measuring lipoproteins in the sample is a polyene.

- 12. (Amended) The method according to claim 10 [or claim 11], wherein the polyene is selected from the group consisting of nystatin, filipin, pimacyllin, pentamycin, trichomycin, fungichromin, perimycin, amphotericin, etoluscomycin, primycin, and candigin.
- 13. (Amended) The method according to claim 1 [or claim 6], wherein the compound having a relatively strong affinity with the non-measuring lipoproteins in the sample is a peptide.
- 15. (Amended) The method according to claim 1 [or claim 6], wherein the compound having a relatively strong affinity with the non-measuring lipoproteins in the sample is a lectin.--